Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
synthetic progestin |
| gptkbp:approvedBy |
1971 (US)
|
| gptkbp:ATCCode |
L02AB01
|
| gptkbp:availableOn |
gptkb:tablet
oral suspension |
| gptkbp:brand |
Megace
Megace ES Megace OS |
| gptkbp:CASNumber |
595-33-5
|
| gptkbp:category |
gptkb:progestogen
antineoplastic agent appetite stimulant |
| gptkbp:chemicalClass |
pregnane steroid
|
| gptkbp:contraindication |
pregnancy
hypersensitivity |
| gptkbp:developedBy |
gptkb:Squibb
|
| gptkbp:discoveredIn |
1960s
|
| gptkbp:eliminationHalfLife |
20-50 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:hasMolecularFormula |
C24H32O4
|
| https://www.w3.org/2000/01/rdf-schema#label |
megestrol acetate
|
| gptkbp:IUPACName |
17-acetyloxy-6-methylpregna-4,6-diene-3,20-dione
|
| gptkbp:KEGGID |
D00423
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
progestogenic activity
glucocorticoid activity |
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
X (contraindicated)
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1423
38244 41926 DB00351 |
| gptkbp:relatedTo |
gptkb:medroxyprogesterone_acetate
megestrol |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
edema
hypertension weight gain hyperglycemia thromboembolism |
| gptkbp:UNII |
EA6LD1M70M
|
| gptkbp:usedFor |
cachexia
appetite stimulation palliative treatment of advanced breast cancer palliative treatment of endometrial cancer treatment of anorexia weight loss in AIDS patients |
| gptkbp:bfsParent |
gptkb:medroxyprogesterone_acetate
|
| gptkbp:bfsLayer |
7
|